To investigate the influence of HSCT/TBI on size-corrected BMD in childhood leukaemia survivors
• Size of patient must be taken into account to avoid over diagnosis of osteopenia when assessing BMD in cancer survivors.
• Treatment effects on peak bone mass in survivors need further evaluation. • Total-BMAD (BMAD T )=BMC/total body BA^2/ height (Ref: Katzman et al.J Clin Endocrinol Metab 1991 :73:1332 -1339 • Lumbar spine-BMAD (BMAD L2-4 )=BMD L2-4 x[4/(π x width)] (Ref: Carter et al. Bone Miner Res. 1992; 7: 137-145.) Analysis: Student's t-tests, Pearson's correlations Approval: Regional Research Ethics Committee However, size corrected is needed for interpretation as total-BMD correlated positively with height-SDS, weight-SDS, fat and lean masses (all p<0.001).
Table 3. BMAD was not associated with treatment factors, vitamin D levels or endocrinopathies in HSCT survivors identified
There were no mean(SD) differences in size-corrected BMD between HSCT and chemotherapy-only patients (Figures 3 and 4) . • Childhood HSCT/TBI survivors have multiple risk factors for reduced bone mineral density (BMD) and poor growth.
• Reduced Z-scores from Dual energy X-Ray absorptiometry (DEXA) have been reported. • However, smaller bones have apparently lower areal BMD than larger ones (figure 1). DEXA measurements may be difficult to interpret in childhood HSCT/TBI survivors who are often short.
• Bone mineral apparent density (BMAD) allows correction of BMD for size in patients with short stature.
